Fluorescent In Situ Hybridization in Surgical Pathology Practice

Gozzetti, 2000, Fluorescence in situ hybridization: uses and limitations, Semin Hematol, 37, 320, 10.1016/S0037-1963(00)90013-1

Meldrum, 2011, Next-generation sequencing for cancer diagnostics: a practical perspective, Clin Biochem Rev, 32, 177

Goswami, 2016, Identification of factors affecting the success of next-generation sequencing testing in solid tumors, Am J Clin Pathol, 145, 222, 10.1093/ajcp/aqv023

Papouchado, 2010, Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility, Am J Surg Pathol, 34, 767, 10.1097/PAS.0b013e3181d96231

Gong, 2005, Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility, Mod Pathol, 18, 1015, 10.1038/modpathol.3800432

Mardis, 2011, A decade’s perspective on DNA sequencing technology, Nature, 470, 198, 10.1038/nature09796

Do, 2015, Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization, Clin Chem, 61, 64, 10.1373/clinchem.2014.223040

Aziz, 2015, College of American Pathologists’ laboratory standards for next-generation sequencing clinical tests, Arch Pathol Lab Med, 139, 481, 10.5858/arpa.2014-0250-CP

Srinivasan, 2002, Effect of fixatives and tissue processing on the content and integrity of nucleic acids, Am J Pathol, 161, 1961, 10.1016/S0002-9440(10)64472-0

Einaga, 2017, Assessment of the quality of DNA from various formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation, PLoS One, 12, e0176280, 10.1371/journal.pone.0176280

Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984

Wolff, 2014, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, Arch Pathol Lab Med, 138, 241, 10.5858/arpa.2013-0953-SA

Singh, 2013, Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies, Ann Diagn Pathol, 17, 322, 10.1016/j.anndiagpath.2013.02.001

Press, 2016, HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists Guidelines with FISH scores used for enrollment in Breast Cancer International Research Group Clinical Trials, J Clin Oncol, 34, 3518, 10.1200/JCO.2016.66.6693

Bartley, 2017, HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology, J Clin Oncol, 35, 446, 10.1200/JCO.2016.69.4836

Bartley, 2016, HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology, Arch Pathol Lab Med, 140, 1345, 10.5858/arpa.2016-0331-CP

Ruschoff, 2012, HER2 testing in gastric cancer: a practical approach, Mod Pathol, 25, 637, 10.1038/modpathol.2011.198

Luk, 2016, Salivary duct carcinoma: clinicopathologic features, morphologic spectrum, and somatic mutations, Head Neck, 38, E1838

Chou, 2013, Clinical and molecular characterization of HER2 amplified-pancreatic cancer, Genome Med, 5, 78, 10.1186/gm482

Li, 2016, HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers, J Thorac Oncol, 11, 414, 10.1016/j.jtho.2015.10.025

McAlpine, 2009, HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy, BMC Cancer, 9, 433, 10.1186/1471-2407-9-433

Cooper, 2013, Molecular biology of lung cancer, J Thorac Dis, 5, S479

Lindeman, 2013, Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology, J Thorac Oncol, 8, 823, 10.1097/JTO.0b013e318290868f

Selinger, 2017, Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target, Histopathology, 70, 402, 10.1111/his.13076

Selinger, 2013, Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization, Mod Pathol, 26, 1545, 10.1038/modpathol.2013.87

Kohno, 2015, Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer, Transl Lung Cancer Res, 4, 156

Selinger, 2015, Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing, Histopathology, 67, 654, 10.1111/his.12708

Peled, 2012, Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer, J Thorac Oncol, 7, e14, 10.1097/JTO.0b013e3182614ab5

Italiano, 2016, Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study, Lancet Oncol, 17, 532, 10.1016/S1470-2045(15)00583-5

Vargas, 2016, Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases, Histopathology, 69, 1000, 10.1111/his.13031

Fisher, 2014, The diversity of soft tissue tumours with EWSR1 gene rearrangements: a review, Histopathology, 64, 134, 10.1111/his.12269

Noujaim, 2017, The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities, Br J Cancer, 116, 669, 10.1038/bjc.2017.4

Antonescu, 2017, Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases, Am J Surg Pathol, 41, 941, 10.1097/PAS.0000000000000846

Yamada, 2017, Histological and immunohistochemical characteristics of undifferentiated small round cell sarcomas associated with CIC-DUX4 and BCOR-CCNB3 fusion genes, Virchows Arch, 470, 373, 10.1007/s00428-017-2072-8

Clay, 2015, MDM2 amplification in problematic lipomatous tumors: analysis of FISH testing criteria, Am J Surg Pathol, 39, 1433, 10.1097/PAS.0000000000000468

Yoshida, 2010, Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics, Mod Pathol, 23, 1279, 10.1038/modpathol.2010.124

Duhamel, 2012, Frequency of mouse double minute 2 (MDM2) and mouse double minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes, Histopathology, 60, 357, 10.1111/j.1365-2559.2011.04023.x

Sukov, 2008, Frequency of USP6 rearrangements in myositis ossificans, brown tumor, and cherubism: molecular cytogenetic evidence that a subset of “myositis ossificans-like lesions” are the early phases in the formation of soft-tissue aneurysmal bone cyst, Skeletal Radiol, 37, 321, 10.1007/s00256-007-0442-z

Erickson-Johnson, 2011, Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion, Lab Invest, 91, 1427, 10.1038/labinvest.2011.118

Salgado, 2011, Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization methodologies, Genes Chromosomes Cancer, 50, 510, 10.1002/gcc.20874

Chen, 2012, Loss of retinoblastoma protein expression in spindle cell/pleomorphic lipomas and cytogenetically related tumors: an immunohistochemical study with diagnostic implications, Am J Surg Pathol, 36, 1119, 10.1097/PAS.0b013e31825d532d

Wang, 2012, Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data, Genes Chromosomes Cancer, 51, 127, 10.1002/gcc.20937

Lovly, 2014, Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions, Cancer Discov, 4, 889, 10.1158/2159-8290.CD-14-0377

Downs-Kelly, 2009, The utility of FOXO1 fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded specimens in the diagnosis of alveolar rhabdomyosarcoma, Diagn Mol Pathol, 18, 138, 10.1097/PDM.0b013e31818c2ea4

Doyle, 2016, Nuclear expression of CAMTA1 distinguishes epithelioid hemangioendothelioma from histologic mimics, Am J Surg Pathol, 40, 94, 10.1097/PAS.0000000000000511

Doyle, 2012, MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement, Am J Surg Pathol, 36, 1444, 10.1097/PAS.0b013e3182562bf8

Doyle, 2014, Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics, Mod Pathol, 27, 390, 10.1038/modpathol.2013.164

Yoon, 2008, MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type, Histopathology, 53, 205, 10.1111/j.1365-2559.2008.03076.x

Swerdlow, 2016, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, 2375, 10.1182/blood-2016-01-643569

Ferry, 2006, Burkitt’s lymphoma: clinicopathologic features and differential diagnosis, Oncologist, 11, 375, 10.1634/theoncologist.11-4-375

Remstein, 2006, The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America, Am J Surg Pathol, 30, 1546, 10.1097/01.pas.0000213275.60962.2a

Skalova, 2010, Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity, Am J Surg Pathol, 34, 599, 10.1097/PAS.0b013e3181d9efcc

Amatu, 2016, NTRK gene fusions as novel targets of cancer therapy across multiple tumour types, ESMO Open, 1, e000023, 10.1136/esmoopen-2015-000023

Gupta, 2015, Salivary gland lesions: recent advances and evolving concepts, Oral Surg Oral Med Oral Pathol Oral Radiol, 119, 661, 10.1016/j.oooo.2015.02.481

Seethala, 2010, A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas, Am J Surg Pathol, 34, 1106, 10.1097/PAS.0b013e3181de3021

Antonescu, 2011, EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland, Genes Chromosomes Cancer, 50, 559, 10.1002/gcc.20881

Mitani, 2010, Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance, Clin Cancer Res, 16, 4722, 10.1158/1078-0432.CCR-10-0463

Voz, 1998, The recurrent translocation t(5;8)(p13;q12) in pleomorphic adenomas results in upregulation of PLAG1 gene expression under control of the LIFR promoter, Oncogene, 16, 1409, 10.1038/sj.onc.1201660

Lai, 2004, Analysis of gestational trophoblastic disease by genotyping and chromosome in situ hybridization, Modern Pathology, 17, 40, 10.1038/modpathol.3800010

Hui, 2010, Molecular diagnosis of gestational trophoblastic disease, Expert Rev Mol Diagn, 10, 1023, 10.1586/erm.10.93

Buza, 2014, Immunohistochemistry and other ancillary techniques in the diagnosis of gestational trophoblastic diseases, Semin Diagn Pathol, 31, 223, 10.1053/j.semdp.2014.03.004

Gupta, 2012, Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis for both recently trained and experienced gynecologic pathologists, Am J Surg Pathol, 36, 1747, 10.1097/PAS.0b013e31825ea736

Bifulco, 2008, Genotypic analysis of hydatidiform mole: an accurate and practical method of diagnosis, Am J Surg Pathol, 32, 445, 10.1097/PAS.0b013e3181520034

Nucci, 2007, Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms, Am J Surg Pathol, 31, 65, 10.1097/01.pas.0000213327.86992.d1

Schoolmeester, 2015, Analysis of MDM2 amplification in 43 endometrial stromal tumors: a potential diagnostic pitfall, Int J Gynecol Pathol, 34, 576, 10.1097/PGP.0000000000000187

Croce, 2013, YWHAE rearrangement identified by FISH and RT-PCR in endometrial stromal sarcomas: genetic and pathological correlations, Mod Pathol, 26, 1390, 10.1038/modpathol.2013.69

Shah, 2009, Mutation of FOXL2 in granulosa-cell tumors of the ovary, N Engl J Med, 360, 2719, 10.1056/NEJMoa0902542

Rosario, 2013, Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expression, Gynecol Oncol, 131, 325, 10.1016/j.ygyno.2013.08.031

Kobel, 2009, Adult-type granulosa cell tumors and FOXL2 mutation, Cancer Res, 69, 9160, 10.1158/0008-5472.CAN-09-2669

Conlon, 2016, Loss of SMARCA4 expression is both sensitive and specific for the diagnosis of small cell carcinoma of ovary, hypercalcemic type, Am J Surg Pathol, 40, 395, 10.1097/PAS.0000000000000558

Foulkes, 2014, No small surprise—small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour, J Pathol, 233, 209, 10.1002/path.4362

Ramos, 2014, Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4, Nat Genet, 46, 427, 10.1038/ng.2928

Witkowski, 2014, Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type, Nat Genet, 46, 438, 10.1038/ng.2931

Kupryjańczyk, 2013, Ovarian small cell carcinoma of hypercalcemic type—evidence of germline origin and smarca4 gene inactivation. A pilot study, Polish J Pathol, 64, 238, 10.5114/pjp.2013.39331

Jelinic, 2014, Recurrent SMARCA4 mutations in small cell carcinoma of the ovary, Nat Genet, 46, 424, 10.1038/ng.2922

Hasselblatt, 2011, Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression, Am J Surg Pathol, 35, 933, 10.1097/PAS.0b013e3182196a39

Weller, 2015, Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups, Acta Neuropathol, 129, 679, 10.1007/s00401-015-1409-0

Smith, 2000, Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas, J Clin Oncol, 18, 636, 10.1200/JCO.2000.18.3.636

Woehrer, 2011, FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice—a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS), Clin Neuropathol, 30, 47, 10.5414/NPP30047

Griffin, 2006, Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss, J Neuropathol Exp Neurol, 65, 988, 10.1097/01.jnen.0000235122.98052.8f

Jenkins, 2006, A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma, Cancer Res, 66, 9852, 10.1158/0008-5472.CAN-06-1796

Louis, 2016, The 2016 World Health Organization classification of tumors of the central nervous system: a summary, Acta Neuropathol, 131, 803, 10.1007/s00401-016-1545-1

Perry, 2004, Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma, Cancer, 101, 2318, 10.1002/cncr.20625

Perry, 2009, Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases, Brain Pathol, 19, 81, 10.1111/j.1750-3639.2008.00167.x

Jones, 2008, Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas, Cancer Res, 68, 8673, 10.1158/0008-5472.CAN-08-2097

Cin, 2011, Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma, Acta Neuropathol, 121, 763, 10.1007/s00401-011-0817-z

Jones, 2009, Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma, Oncogene, 28, 2119, 10.1038/onc.2009.73

Virk, 2015, Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing, PLoS One, 10, e0124178, 10.1371/journal.pone.0124178

Zacher, 2017, Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel, Brain Pathol, 27, 146, 10.1111/bpa.12367

Nikiforova, 2016, Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors, Neuro-oncol, 18, 379, 10.1093/neuonc/nov289

Dubbink, 2016, Diagnostic detection of allelic losses and imbalances by next-generation sequencing: 1p/19q co-deletion analysis of gliomas, J Mol Diagn, 18, 775, 10.1016/j.jmoldx.2016.06.002

Srigley, 2013, The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia, Am J Surg Pathol, 37, 1469, 10.1097/PAS.0b013e318299f2d1

Kinney, 2015, Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma, Mod Pathol, 28, 1236, 10.1038/modpathol.2015.81

Gowrishankar, 2015, A genomic algorithm for the molecular classification of common renal cortical neoplasms: development and validation, J Urol, 193, 1479, 10.1016/j.juro.2014.11.099

Petersson, 2010, Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases, Virchows Arch, 456, 355, 10.1007/s00428-010-0898-4

Argani, 2015, MiT family translocation renal cell carcinoma, Semin Diagn Pathol, 32, 103, 10.1053/j.semdp.2015.02.003

Marino-Enriquez, 2011, ALK rearrangement in sickle cell trait-associated renal medullary carcinoma, Genes Chromosomes Cancer, 50, 146, 10.1002/gcc.20839

Sukov, 2012, ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients, Mod Pathol, 25, 1516, 10.1038/modpathol.2012.107